Campos-Salazar Antony Brayan, Genvigir Fabiana Dalla Vecchia, Felipe Claudia Rosso, Tedesco-Silva Helio, Medina-Pestana José, Monteiro Gabriela Vieira, Basso Rodrigo de Gouveia, Cerda Alvaro, Hirata Mario Hiroyuki, Hirata Rosario Dominguez Crespo
School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Bioinformatics and Pharmacogenetics Laboratory, METOSMOD Research Group, School of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Front Pharmacol. 2018 Nov 14;9:1296. doi: 10.3389/fphar.2018.01296. eCollection 2018.
Monitoring of immunosuppressive drugs, such as calcineurin and mTOR inhibitors, is essential to avoid undesirable kidney transplant outcomes. Polymorphisms in pharmacokinetics-related genes have been associated with variability in blood levels of immunosuppressive drugs and adverse effects, but influence of pharmacodynamics-related genes remains to be elucidated. The influence of polymorphisms in genes of the mTOR and calcineurin signaling pathways on long-term clinical outcomes was investigated in Brazilian kidney transplant recipients within the 1-year post-transplant. Two-hundred and sixty-nine kidney transplant recipients were enrolled at a kidney transplant center in São Paulo city, Brazil, and treated with tacrolimus plus everolimus or mycophenolate sodium (clinical trial NCT01354301). Clinical and laboratory data, including renal function parameters and drug blood levels were recorded. Genomic DNA was extracted from blood samples. Polymorphisms in rs1057079 (c.4731G>A), rs1135172 (c.1437T>C), and rs1064261 (c.2997C>T); rs3730251 (c.249G>A); rs6033557 (n.259+24936T>C); rs2159370 (c.-2110G>T); and rs3761548 (c.-23+2882A>C) and rs2232365 (c.-22-902A>G) were analyzed by real-time PCR. Frequencies of gene polymorphisms did not differ among the treatment groups. Analysis of primary outcomes showed that patients carrying c.1437CC and c.-23+2882CC genotypes had higher serum creatinine than non-carriers ( < 0.05) at 1-year post-transplant. c.4731G allele (AG+GG genotype) was associated with increased risk for acute rejection (OR = 3.53, 95% CI = 1.09-11.48, = 0.037). Moreover, 1-year cumulative incidence of rejection was higher in c.4731G allele carriers compared to AA genotype carriers ( = 0.027). Individually, analysis of secondary outcomes revealed that c.-2110GG genotype carriers had higher risk of leukopenia, n.259+24936C allele carriers had increased risk of constipation, and c.-22-902A or c.-23+2882A allele had higher risk of gastrointestinal disorders ( < 0.05). However, these results were not maintained in the multivariable analysis after -value adjustment. In conclusion, variants in genes of mTOR and calcineurin pathways are associated with long-term impaired renal function, increased risk of acute rejection, and, individually, with adverse events in Brazilian kidney transplant recipients.
监测免疫抑制药物,如钙调神经磷酸酶抑制剂和mTOR抑制剂,对于避免肾移植出现不良后果至关重要。药代动力学相关基因的多态性与免疫抑制药物血药浓度的变异性及不良反应有关,但药效学相关基因的影响仍有待阐明。在巴西肾移植受者移植后1年内,研究了mTOR和钙调神经磷酸酶信号通路基因多态性对长期临床结局的影响。在巴西圣保罗市的一个肾移植中心招募了269名肾移植受者,给予他克莫司联合依维莫司或麦考酚钠治疗(临床试验NCT01354301)。记录临床和实验室数据,包括肾功能参数和药物血药浓度。从血样中提取基因组DNA。通过实时PCR分析rs1057079(c.4731G>A)、rs1135172(c.1437T>C)和rs1064261(c.2997C>T);rs3730251(c.249G>A);rs6033557(n.259+24936T>C);rs2159370(c.-2110G>T);以及rs3761548(c.-23+2882A>C)和rs2232365(c.-22-902A>G)的多态性。基因多态性频率在各治疗组之间无差异。主要结局分析显示,携带c.1437CC和c.-23+2882CC基因型的患者在移植后1年时血清肌酐高于非携带者(P<0.05)。c.4731G等位基因(AG+GG基因型)与急性排斥反应风险增加相关(OR = 3.53,95%CI = 1.09 - 11.48,P = 0.037)。此外,与AA基因型携带者相比,c.4731G等位基因携带者的1年累积排斥发生率更高(P = 0.027)。单独分析次要结局发现,c.-2110GG基因型携带者白细胞减少风险更高,n.259+24936C等位基因携带者便秘风险增加,c.-22-902A或c.-23+2882A等位基因胃肠道疾病风险更高(P<0.05)。然而,在P值调整后的多变量分析中,这些结果未得到维持。总之,mTOR和钙调神经磷酸酶途径基因变异与巴西肾移植受者的长期肾功能受损、急性排斥反应风险增加以及个别不良事件相关。